Migraine – Unmet Need – Unmet Need – Migraine Prophylaxis (US/EU)

Prophylactic treatment of migraine is mainly considered for chronic migraine patients or those with episodic migraine who have long-lasting attacks or do not experience sufficient relief with acute therapies alone. Most of the branded prophylactic treatments for migraine such as the CGRP-targeted therapies showed efficacy largely comparable to that of generic drugs in cross-trial comparisons, although they have proven efficacious in later lines of therapy after patients fail first-line generic options. In addition, most patients only partially respond to these therapies and fail to experience complete pain relief and will, therefore, often rely on acute drugs for breakthrough attacks. Need exists for prophylactic therapies that are more efficacious and tolerable and that target refractory pain. Our content provides quantitative insights into key treatment drivers and goals and the current level of unmet need, based on the perceptions of U.S. and European neurologists. In this report, we analyze the commercial opportunities in the prophylactic treatment of migraine and how emerging therapies can capitalize on these opportunities.

QUESTIONS ANSWERED

• What are the treatment drivers and goals for migraine prophylaxis?
• Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
• How do current therapies perform on key treatment drivers and goals for migraine prophylaxis?
• What are the prevailing areas of unmet need and opportunity in migraine prophylaxis?
• What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new drug for the prophylactic treatment of migraine?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 61 U.S. and 31 European neurologists fielded in December 2022

Key companies: Eli Lilly, Teva, AbbVie, Amgen / Novartis, and Pfizer

Key drugs: Aimovig, Emgality, Ajovy, Botox, Nurtec ODT, and Qulipta